News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
AustCancer Commences Phase II Clinical Study Of RP101 For Metastatic Pancreatic Cancer
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SYDNEY, Australia--(BUSINESS WIRE)--Dec. 14, 2004--Australian Cancer Technology ("AustCancer") (ASX:ACU) today said it has initiated a Phase II clinical study of RP101 for the treatment of metastatic pancreatic cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Insights
Rethinking hair loss treatment
June 4, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Funding
NewLimit snags $435M after seeing age reversal in human liver cells
June 3, 2026
·
2 min read
·
Gabrielle Masson
Breast cancer
Celcuity slides even after ‘practice-changing’ late-stage breast cancer data
June 3, 2026
·
2 min read
·
Tristan Manalac
CAR-T
Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study
June 3, 2026
·
2 min read
·
Tristan Manalac
